Organon & CO 8-K filings

Organon & Co. provides supplemental non-GAAP financial metrics for Q2 2026, detailing Adjusted EBITDA and other key performance indicators ahead of its merger with Sun Pharmaceutical Industries Limited.

Organon & Co. stockholders overwhelmingly approved the merger agreement with Sun Pharmaceutical Industries Limited at a special meeting held on July 23, 2026.

Organon & Co. provides an update on its merger with Sun Pharma, including supplemental disclosures to its proxy statement and details on ongoing litigation.

Organon & Co. stockholders approved an amendment and restatement of the 2021 Incentive Stock Plan, increasing the share pool by 8 million shares.

Organon & Co. reported Q1 2026 revenue of $1.46 billion, down 4% year-over-year, impacted by declines in Women's Health, while announcing a pending merger with Sun Pharmaceutical Industries expected in early 2027.

Sun Pharmaceutical Industries Limited announced a definitive agreement to acquire Organon & Co. for $14.00 per share in an all-cash transaction, valuing Organon at an enterprise valuation of $11.75 billion.

Organon & Co.'s Audit Committee completed its independent review into biosimilar purchase timing, finding no improper conduct or need for financial statement adjustments.

Organon & Co. announced its fourth quarter and full year 2025 financial results, reporting a net loss in Q4 due to a significant goodwill impairment and projecting flat revenue for 2026.

Organon & Co. reported a 1% revenue increase for Q3 2025 but revised its full-year 2025 revenue and Adjusted EBITDA margin guidance downwards.

Organon & Co. announced that director Grace Puma will not stand for re-election at the company's 2026 Annual Meeting of Stockholders.

Organon & Co. filed an amended 8-K to disclose that Executive Chair Carrie S. Cox will receive a base salary of $100,000 per month.

Organon's CEO Kevin Ali resigned following an investigation into improper wholesaler sales practices, leading to the appointment of Joseph Morrissey as Interim CEO and Carrie Cox as Executive Chair.

Organon reported mixed Q2 2025 results with a slight revenue decline but raised full-year revenue guidance and made significant progress on debt reduction.

Organon & Co. stockholders approved an amended incentive stock plan increasing available shares by 7.8 million and re-elected all eleven director nominees at the company's 2025 Annual Meeting.

Organon & Co. announced that the U.S. FDA has granted full interchangeability designation to its biosimilar HADLIMA (adalimumab-bwwd) with all presentations of Humira (adalimumab), enabling direct pharmacy substitution and potentially increasing patient access and healthcare savings.

Organon affirms its full-year 2025 financial guidance and resets its dividend payout to strengthen its capital structure after reporting first-quarter results.

Organon & Co. has appointed Ramona A. Sequeira to its Board of Directors, effective July 1, 2025, increasing the board size to 12.

Organon & Co. announced its fourth quarter and full year 2024 results, with full year revenue of $6.4 billion, up 2% as-reported and 3% at constant currency, and provided financial guidance for 2025.

Organon & Co. has announced that Susanne Fiedler will step down as Chief Commercial Officer, effective January 15, 2025, and will transition to a senior advisor role until her expected departure on or about April 30, 2025.

Organon & Co.'s Board of Directors has reduced its size to eleven members following the resignation of Martha E. McGarry.

Martha E. McGarry has resigned from Organon & Co.'s Board of Directors and Talent Committee, effective immediately, with no indication of disagreement with the company.

The FDA has extended the review period for Organon's VTAMA cream for atopic dermatitis by three months, with a new target action date of March 12, 2025.

Organon & Co. announced a 4% increase in third-quarter revenue, reaching $1.582 billion, and raised the midpoint of its full-year revenue guidance by $50 million.

Organon & Co. has agreed to acquire Dermavant Sciences Ltd. for up to $1.2 billion, including upfront and milestone payments, to expand its presence in the dermatology market.

Organon's second quarter 2024 results show flat revenue year-over-year, but a 2% increase at constant currency, with notable growth in biosimilars and women's health segments.

Organon & Co. held its 2024 Annual Meeting on June 4, 2024, where shareholders elected directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the company's auditor.

Organon & Co. successfully closed a $1 billion private offering of senior secured and unsecured notes and amended its senior secured credit agreement, extending the maturity of its term loan and revolving credit facility.

Organon & Co. announced a 7% revenue increase at constant currency for the first quarter of 2024, driven by growth in Women's Health and Biosimilars.

Organon & Co. announced its fourth quarter and full year 2023 results, showing revenue growth but a decrease in adjusted EBITDA margin, while providing 2024 guidance for continued revenue growth and stable to improving EBITDA margins.